Activation of a local renin angiotensin system in podocytes by glucose.
ANG II is a critical mediator of diabetic nephropathy. Pharmacologic inhibition of ANG II slows disease progression beyond what could be predicted by the blood pressure lowering effects alone, suggesting the importance of nonhemodynamic pathways of ANG II in mediating disease. Podocyte injury and loss are cardinal features of diabetic nephropathy. Mounting evidence suggests that the podocyte is a direct target of ANG II-mediated signaling in diabetic renal disease. We have tested the hypothesis that high glucose leads to the activation of a local angiotensin system in podocytes and delineated the underlying pathways involved. Cultured podocytes were exposed to standard glucose (5 mM), high glucose (40 mM), or mannitol as an osmotic control. ANG II levels in cell lysates were measured in the presence or absence of inhibitors of angiotensin-converting enzyme (captopril), chymase (chymostatin), and renin (aliskiren) activity. The effects of glucose on renin and angiotensin subtype 1 receptor expression and protein levels were determined. Exposure to high glucose resulted in a 2.1-fold increase ANG II levels mediated through increased renin activity, as exposure to high glucose increased renin levels and preincubation with Aliskiren abrogated glucose-induced ANG II production. Relevance to the in vivo setting was demonstrated by showing glomerular upregulation of the prorenin receptor in a podocyte distribution early in the course of experimental diabetic nephropathy. Furthermore, high glucose increased angiotensin subtype 1 receptor levels by immunofluorescence and Western blot. Taken together, the resultant activation of a local renin angiotensin system by high glucose may promote progressive podocyte injury and loss in diabetic nephropathy.
Durvasula
Raghu V
RV
Univ. of Washington School of Medicine, Division of Nephrology, Box 356521, Seattle, WA 98195, USA. rdrvsula@u.washington.edu
Shankland
Stuart J
SJ
D000804:Angiotensin II / Q000235:genetics* / Q000494:pharmacology / Q000502:physiology; D000818:Animals; D002478:Cells, Cultured; D017931:DNA Primers; D003928:Diabetic Nephropathies / Q000209:etiology* / Q000503:physiopathology; D005947:Glucose / Q000494:pharmacology*; D007668:Kidney / Q000187:drug effects / Q000502:physiology* / Q000503:physiopathology; D051379:Mice; D050199:Podocytes / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger / Q000235:genetics; D012083:Renin / Q000235:genetics*; D012084:Renin-Angiotensin System / Q000187:drug effects / Q000502:physiology*
D017931:DNA Primers; D012333:RNA, Messenger; D000804:Angiotensin II; D012083:Renin; D005947:Glucose